Testing a new eye drop for glaucoma or high eye pressure

This trial tests a new eye drop combination (TFC-003) to lower eye pressure in people with primary open-angle glaucoma or ocular hypertension. It compares the new drug to existing treatments to see if it works better or is safer.

This study tests a new eye drop against an existing one to see which better lowers eye pressure in people with open-angle glaucoma or ocular hypertension. You may be able to join if you have high eye pressure in both eyes that needs treatment and you are at least 18 years old.

This trial tests an investigational drug called REGN22530 for people with mild to moderate primary open-angle glaucoma or ocular hypertension (high eye pressure). The goal is to see if it can safely lower eye pressure and protect vision.

This study checks whether a device called the Nanodropper helps deliver glaucoma medicine as well as standard use. It is for adults with stable primary open-angle glaucoma (or ocular hypertension) who are on a limited number of eye-pressure medicines.

This Phase 3 study compares two versions of the same glaucoma eye-drop medicine (bimatoprost 0.01%) to see how similarly they work and their effect on eye pressure. It may help people with chronic open-angle glaucoma or ocular hypertension who need treatment in both eyes.

This study tests a new eye drop medicine (DNN.31.19.026) to lower pressure inside the eye for people with glaucoma or ocular hypertension. The goal is to see if it works safely when combined with other eye pressure medications.